Kaléo is facing congressional scrutiny for the price of its naloxone delivery device Evzio, reports Fortune.
The device, intended to counteract the effects of an opioid overdose, costs $4,500 for a pack of two. In 2014, a two-pack cost only $690, according to the report.
More than 30 U.S. senators on Wednesday sent a letter to Kaléo criticizing the device's high list price and asking for more information on the company's pricing strategies.
"Such a steep rise in the cost of this drug threatens to price-out families and communities that depend on naloxone to save lives," the senators wrote in the letter. Many of the senators represent states deeply affected by the ongoing opioid epidemic.
Kaléo argues its patient assistance efforts, including large patient discounts and few out-of-pocket costs, justify the list prices for its products, reports Fortune.
More articles on supply chain:
Supply chain tip of the week: 9 questions to test your inventory management IQ
10 statistics on drug, device recalls in Q4
6 quotes from Pfizer CEO on Trump, drug prices and more